Centre Of Research Excellence In Pulmonary And Environmental Medicine.
Funder
National Health and Medical Research Council
Funding Amount
$2,007,200.00
Summary
This Centre will study inhalational lung diseases, ie diseases caused by substances such as asbestos, cigarette smoke, air pollutants and allergens. Australia has of the highest incidences in the world of at least 2 of the diseases to be studied, asbestos- and allergen-induced lung diseases. These two alone are estimated to cost the Australian economy over $100 million -yr and $1 billion respectively in direct health costs plus loss of productivity and compensation. Furthermore COPD on of our ot ....This Centre will study inhalational lung diseases, ie diseases caused by substances such as asbestos, cigarette smoke, air pollutants and allergens. Australia has of the highest incidences in the world of at least 2 of the diseases to be studied, asbestos- and allergen-induced lung diseases. These two alone are estimated to cost the Australian economy over $100 million -yr and $1 billion respectively in direct health costs plus loss of productivity and compensation. Furthermore COPD on of our other major areas of interest is the 4th leading cause of death in males and conservatively costs the economy over one billion dollars per year as well as being the leading cause of disability in the elderly. It is predicted that COPD will be the 4th most common disease worldwide by 2020. As such this area of study is important for Australia and internationally and any advances will deliver major economic and health benefits. We will study the role of blood and sputum tests in the diagnosis, monitoring, screening and management of lung diseases caused by asbestos, cigarette smoke, air pollutants and allergens ie. mesothelioma, asthma, COPD and lung cancer. We will apply modern DNA 'gene chip' methods to study the pathogenesis of these diseases and help us to identify new treatment targets. This will also be used to guide genetic searches for polymorphism's, spliced variants and DNA modification(epigentics) in COPD and lung cancer. Genetic studies of sensitivity to air pollution will be used to define at risk patients We will also evaluate how the method of cell death that occurs during some therapies eg. in cancer and allergy-asthma, might alter how the body responds and thus help us develop novel therapeutic strategies for these diseases. This research program should lead to new tests and treatments and at the same time promote the training of a new generation of young researchers in this field and so ensure that the work continues long termRead moreRead less
Clinical Utility Of A Novel Serum Marker, Serum Mesothelin Family Protein (SMF) In Mesothelioma Patients
Funder
National Health and Medical Research Council
Funding Amount
$323,250.00
Summary
Asbestos fibres can cause a number of cancers, one of the most aggressive and untreatable being mesothelioma. Unfortunately mesothelioma is largely resistant to the main forms of therapy: surgery, chemotherapy and radiation treatment. The average survival from diagnosis is only 8.5 months. It is sometimes difficult to diagnose mesothelioma and additional tests would be useful. Also, a simple screening test may be able to detect the earlier stages of this disease, and allow for early treatment, w ....Asbestos fibres can cause a number of cancers, one of the most aggressive and untreatable being mesothelioma. Unfortunately mesothelioma is largely resistant to the main forms of therapy: surgery, chemotherapy and radiation treatment. The average survival from diagnosis is only 8.5 months. It is sometimes difficult to diagnose mesothelioma and additional tests would be useful. Also, a simple screening test may be able to detect the earlier stages of this disease, and allow for early treatment, would be of widespread value to the community. Markers of cancer can be detected in the blood for a number of cancers e.g. prostate, colon, liver and ovary. No reliable serum marker for the presence of mesothelioma has been described and this study describes work aimed at further evaluating a novel marker that we have been researching in collaboration with a group from Seattle, USA. Mesothelin is a protein made in mesothelial tissue such as mesothelioma. When an individual develops mesothelioma the levels increase in the blood. Also, a proportion of individuals increased levels of this molecule can be detected prior to presentation. This means that it may become a useful screening tool in asbestos-exposed individuals and might be a clinical indicator of the need for further testing and, if early disease is found, early treatments. Given that early treatment of cancer is more effective than late treatment in most clinical situations, this is likely to improve the prognosis for this disease. For this marker to be clinically useful, a careful correlation between its level in the blood and the exact amount of tumour that is present (based on precised computerised tomography x-ray measurements of the tumour) are important. The findings of this study may have widespread implications for patients with mesothelioma and individuals at risk of developing mesothelioma after exposure to asbestos.Read moreRead less
Epimutations As Germ-line Defects In Hereditary Cancer Syndromes
Funder
National Health and Medical Research Council
Funding Amount
$385,925.00
Summary
Traditionally familial cancers were thought to be caused and inherited by spelling mistakes within the genetic code of cancer prevention genes. Our group has found that a 'chemical coat' around the MLH1 gene, causing it to be switched off, can also be inherited in some cases of bowel cancer, without any mistakes within the gene's code. We will determine if this 'coat' causes other types of cancer and if this runs in families. We also hope to find out how the coat is formed and may be reversed.
Realising The World Health Organisation Targets For Elimination Of Cervical Cancer As A Public Health Problem: Effective Implementation And Scale-up Of HPV Vaccination And Cervical Screening In Australia, Regionally, And Globally
Funder
National Health and Medical Research Council
Funding Amount
$2,125,000.00
Summary
This fellowship focuses on improving cancer screening, particularly the implementation of HPV vaccination and cervical screening. CI Canfell will pursue an Australian, regional and global health agenda towards the elimination of cervical cancer. Her work is supporting the successful implementation of the new cervical screening program in Australia, provides crucial support to other countries in the region, and is directly informing the WHO global elimination strategy.
3D-BrachyView: A 3D Real-time Virtual Reality Intra-operative Quality Assurance System For Brachytherapy
Funder
National Health and Medical Research Council
Funding Amount
$359,105.00
Summary
3D-Brachyview aims to bring 3D virtual reality into the Quality Assurance and training of physicists in prostate cancer brachytherapy. The 3D simultaneous visualisation of the position of the seeds implanted, the actual shape and position of the prostate, and the expected treatment plan, will help doctors to deliver the best treatment possible.
Contribution Of Ovarian Cancer Stem Cells To Chemoresistance And Recurrent Disease.
Funder
National Health and Medical Research Council
Funding Amount
$378,940.00
Summary
Ovarian cancer is the most lethal gynaecological cancer. Previously, we showed that cancer stem cells are the “beating heart” of the ovarian cancer and are responsible for drug resistance and tumour relapse. The ineffective targeting of these cells by chemotherapy is accountable for the poor clinical outcomes in ovarian cancer patients. This project will define the molecular signals involved in maintenance of cancer stem cells and develop targeted therapies against these cells.
E2F Inhibitors As Anticancer Agents For Squamous Cell Carcinoma
Funder
National Health and Medical Research Council
Funding Amount
$257,036.00
Summary
Squamous cell carcinoma of the head and neck is one of the six most frequent causes of cancer death worldwide. these tumours are currently treated with surgery, radiotherapy and chemotherapy. Although these treatments are associated with a five year survival rate of between 40% and 60% there is a critical need for more effective and less destructive treatments. In this application we will extend on our earlier work in which we identified the protein E2F1 as being a major contributor to tumour de ....Squamous cell carcinoma of the head and neck is one of the six most frequent causes of cancer death worldwide. these tumours are currently treated with surgery, radiotherapy and chemotherapy. Although these treatments are associated with a five year survival rate of between 40% and 60% there is a critical need for more effective and less destructive treatments. In this application we will extend on our earlier work in which we identified the protein E2F1 as being a major contributor to tumour development. In normal cells, E2F1 is required for the regulated growth of head and neck cells. However, we found that in head and neck tumours, E2F1 is overactive and contributes to the dergulated growth of the tumour. In this project we will test our newly developed inhibitors of E2F1 on various tumour cells derived from head and neck cancers to see how effective they are at stopping tumour cell growth. Furthermore we will test these compounds in animal models of head and neck cancer to determine whether they will be useful therapeutic agents for treatment of human cancer. Early results on tumour cell lines look very promising.Read moreRead less
Circulatory Biomarkers For Idiopathic Pulmonary Fibrosis: Improving Patient Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$841,625.00
Summary
We are going to find molecules in the blood that would improve the diagnosis and treatment of a lung condition called Idiopathic Pulmonary Fibrosis (IPF). The project brings together well characterized patients from the Australian IPF registry, blood samples we have collected from them and cutting edge technologies to complete this project.